[A prospective study of histological changes after AraAMP treatment in patients with chronic hepatitis B infection].
OBJECTIVE
To investigate the histological changes in liver biopsy tissue induced by AraAMP therapy for 50 days in patients with chronic hepatitis B infection.


METHODS
Eleven patients were enrolled into this prospective study. All the patients had liver biopsy performed within 1 week before starting AraAMP therapy. A second liver biopsy was taken for comparison six months after the end of therapy. Blinded biopsies were scored according to Knodell's histology activity index (HAI), and examined for HBeAg and alpha-smooth muscle actin with immunohistochemistry as well as HBV DNA by using in situ hybridization.


RESULTS
Histological improvement of >or=2 points decrease in the necroinflammatory HAI scores was seen in 8 of the 11 (72.7%) of patients after treatment. In these patients histological assessment revealed a significant improvement in intralobular inflammation and fibrosis as compared with pretreatment values(P < 0.05). There was significant difference of HAI changes in 6 cases graded as G3 based on the degree of periportal interface hepatitis and spotty parenchymal injury, but not in 5 cases graded as G2. HBeAg disappeared from liver tissue in 4 of the 9 cases and a significant reduction of activated liver stellate cells was demonstrated in the second biopsy(P = 0.018). Of the nine cases with HBV DNA positive at the first biopsy with in situ hybridization examination, 4 were negative at the second biopsy.


CONCLUSIONS
Significant improvement in intralobular inflammation and fibrosis can be observed in liver tissue from patients with chronic hepatitis B infection treated with AraAMP.
Lang
Z
Z
Beijing Youan Hospital, Beijing 100054, China.
Xu
R
R
Wang
E
E
Zhang
H
H
Si
C
C
Cui
Z
Z
Tian
G
G
D000293:Adolescent; D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D003561:Cytarabine / Q000627:therapeutic use*; D005260:Female; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000473:pathology*; D006801:Humans; D008099:Liver / Q000473:pathology*; D008297:Male; D011446:Prospective Studies
D000998:Antiviral Agents; D003561:Cytarabine